A Phase 1, Randomized, Open-label, Crossover Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121, Tezacaftor, and Deutivacaftor in Healthy Adult Subjects
Latest Information Update: 15 Dec 2022
At a glance
- Drugs Deutivacaftor/tezacaftor/vanzacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 08 Dec 2022 Status changed from active, no longer recruiting to completed.
- 11 Nov 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Sep 2022 New trial record